

Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer's Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in-development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models.

T3D-959


Evidence Summary

This PPAR modulator may improve peripheral and central metabolic function while avoiding the side effects associated with existing PPAR-targeted drugs, but clinical effects to date have been modest.

Neuroprotective Benefit: T3D-959 has shown modest effects on attenuating AD biomarkers in trials to date. It may mitigate cognitive decline related to cerebral metabolic dysfunction by improving brain metabolism, and reducing neuroinflammation..

Aging and related health concerns: T3D-959 may favorably modulate the peripheral metabolic profile. It shows anti-diabetic activity in preclinical models.

Safety: T3D-959 has been generally safe and well-tolerated in clinical trials, thus far. Possible side effects include muscle weakness and cramps, but were low frequency.

Availability: In clinical trials	Dose: Not established. A dose of 30 mg/day, orally will be tested in a Phase 2/3 trial in AD.	Chemical formula: C ₂₅ H ₂₆ NNaO ₅ MW: 443.5 g/mol  Source: PubChem
Half-life: 14.8-19.9 hours	BBB: Penetrant	
Clinical trials: T3D-959 has been tested in Phase 1 in healthy volunteers (n=96), and Phase 2 trials in Alzheimer's disease (n=34; n=250), with a Phase 2/3 trial planned.	Observational studies: None	

What is it?

T3D-959 is a dual peroxisome proliferator-activated receptor (PPAR) agonist, which acts on PPAR δ and PPAR γ . It is a biased agonist, which is 15 times more potent toward PPAR δ (human ED₅₀ = 19 nM), relative to PPAR γ (human ED₅₀ = 297 nM) [1]. PPARs are involved in the regulation of metabolic homeostasis, particularly lipid metabolism. A class of PPAR γ modulators called thiazolidinediones have been used as anti-diabetic agents, and this dual agonist was originally being developed for diabetes and dyslipidemia by Dara Therapeutics under the name DB959. In 2013, [T3D Therapeutics](#) licensed DB959 from Dara ([Press release](#)), and pivoted clinical development toward Alzheimer's disease. To date, T3D-959 has been tested in Phase 2 trials in mild-to-moderate Alzheimer's disease, with a Phase 2/3 trial in that population planned for 2026.

Neuroprotective Benefit: T3D-959 has shown modest effects on attenuating AD biomarkers in trials to date. It may mitigate cognitive decline related to cerebral metabolic dysfunction by improving brain metabolism, and reducing neuroinflammation.

Types of evidence:

- 2 clinical trials
- 3 laboratory studies

Human research to suggest prevention of dementia, prevention of decline, or improved cognitive function:

PPARs are metabolic regulators and are involved in lipid metabolism in the CNS. PPAR γ activity has also been associated with a variety of neuroprotective effects, including the induction of brain derived neurotrophic factor (BDNF). Although they are not ideal for CNS indications due to their limited bioavailability in the brain and side effect profile [2], the use of thiazolidinediones, also called glitazones, the class of anti-diabetics which primarily act as PPAR γ agonists, has been associated with a reduced incidence of dementia in some populations [3; 4]. The protective effects are likely mediated by an improvement in bioenergetics in the brain, as cerebral hypometabolism is a risk factor and feature of cognitive decline.

Human research to suggest benefits to patients with dementia:

The results of clinical trials testing thiazolidinediones in Alzheimer's disease (AD) were mixed, such that meta-analyses indicate a lack of consistent clinically meaningful cognitive benefit in this population [5]. The overall data suggest that PPAR γ is a reasonable target, however, thiazolidinediones are not the optimal PPAR γ modulators for this population. Furthermore, the PPAR family contains three members, α , δ , and γ , which have overlapping and intertwined roles in the regulation of metabolism. Due to the complex regulatory networks amongst the PPARs, it may be necessary to modulate multiple family members to meaningfully impact brain metabolism and influence cognitive trajectories [6]. The bias of T3D-959 for PPAR δ may offer a better therapeutic profile.

T3D-959, the mixed PPAR δ /PPAR γ agonist, was tested in an exploratory Phase 1/2 clinical trial in patients with mild to moderate AD (n=34) (NCT02560753) [7]. This study tested T3D-959 at oral doses of 3, 10, 30, or 90 mg per day for 14 days, and focused primarily on safety, pharmacokinetics, and pharmacodynamics. Treatment led to dose-dependent changes in the plasma metabolomics profile, including decreases in the branched chain amino acids, isoleucine, leucine, and valine, which are associated with insulin resistance. The ratio of glycine levels (EOT/BL), another measure of insulin resistance, was also increased at the highest dose, consistent with the ability of T3D-959 to improve insulin sensitivity. FDG-PET analyses also indicated dose-dependent regional changes in glucose utilization in the brain in response to treatment. In terms of the lipid profile, there was a decrease in several ceramides, and an increase in fatty acid oxidation. Underpowered exploratory aims assessing

cognitive function found that T3D-959 treatment was associated with improvement on the ADAS-cog11 and the Digit Symbol Substitution Tests (DSST), however, there was no placebo comparator group.

T3D-959 was tested at oral doses of 15, 30, and 45 mg per day in 256 participants with mild to moderate AD in the placebo-controlled, double-blind 24-week Phase 2 (PIONEER)([NCT04251182](#)) trial. T3D-959 did not achieve its primary endpoints regarding improvement on cognition, as measured by the Alzheimer's Disease Assessment Scale 11-task cognitive subscale (ADAS-Cog11), and function, based on the Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC) in the total study population ([Press release](#)). The secondary endpoint of the change in the A β 42/40 ratio was met at the 30 mg dose. Additionally, trends toward benefit on the primary and secondary outcomes were observed in the subpopulation with a high baseline ptau217/non-ptau217 ratio (n=141). In this modified intention-to-treat population (mITT), there was a trend toward slowing of decline on the ADAS-Cog11 relative to placebo in the 30 mg group (n=39) (least squares mean difference 1.97; p=0.073), and a trend towards slowing on the ADCS-CGIC at the 15 mg dose (n=38) (least squares mean difference 0.49; p=0.0601) [8] ([AAIC 2024](#)). There were significant improvements on the secondary endpoint of change in A β 42/40 ratio, and the exploratory synaptic biomarker, plasma neurogranin, in the mITT population at the 30 mg and 45 mg doses. Based on the biomarker results of the mITT, T3D therapeutics will be testing T3D-959 in a Phase 2/3 trial in patients with biomarker validated mild-to-moderate AD ([NCT06964230](#)). The trial is scheduled to initiate in 2026.

Mechanisms of action for neuroprotection identified from laboratory and clinical research:

Alzheimer's disease

T3D-959 has primarily been tested in a metabolic model of AD, where, as a metabolic modulator, it would be expected to be most efficacious. The positive effects in this model suggest that T3D-939 may be most effective in AD patients with co-existing metabolic disease, and/or cerebral hypometabolism, as well as those with an inflammatory endophenotype. Ongoing clinical studies may offer better insight into whether this therapy is beneficial for patients with a variety of AD subtypes, or only those with a particular metabolic/inflammatory profile.

In the rat streptozotocin-induced model of AD, T3D-959 (1 mg/kg/day by oral gavage), improved motor performance on the rotarod test and spatial learning and memory on the Morris water maze, toward control levels [1; 9; 10]. These behavioral effects coincided with the preservation of cortical and white matter structure consistent with decreased neuronal loss. Levels of oxidative stress, A β , and

phosphorylated tau were also reduced with treatment. T3D-959 also restored insulin/IGF signaling and reduced neuroinflammation in this model. The dosing used a therapeutic regimen, with treatment starting at one or seven days following intracerebral streptozotocin, suggesting that T3D-959 may benefit patients in early stages of the disease. Delayed treatment (starting at seven days), appeared to show more benefit in this model, particularly with respect to its effects on the neuroinflammatory profile. Both conditions stimulated anti-inflammatory mediators, such as IL-10, IL-7, and VEGF, but only delayed treatment also suppressed pro-inflammatory mediators, including IFN- γ , M-CSF, MCP-1, and RANTES.

AU9: Similar to T3D-959, AU9 is a dual PPAR δ (EC₅₀ 41 nM) and PPAR γ agonist [11]. AU9 is a partial agonist for PPAR γ , as it avoids Tyrosine-473 of the AF2 ligand binding domain of PPAR γ , which has been associated with many of the side effects of full PPAR γ agonists. In 3xTg AD mice, treatment with AU9 (5 mg/kg, orally) starting at nine months of age attenuated cognitive deficits on the Y-maze and novel object recognition test at 12 months of age. This was accompanied by improvements in measures of synaptic plasticity (LTP) and spine density, as well as increased levels of neurotrophic factors, including BDNF, NGF, and NT3. A β plaque load was also reduced in AU9 treated mice, which may stem from a reduction in beta secretase activity and glial reactivity.

APOE4 interactions: Based on exploratory outcome data for the Phase 1/2 clinical trial in patients with mild to moderate AD, ApoE genotype may influence the efficacy of T3D-959. In a study of plasma metabolomics, the ApoE4 carriers treated with the highest dose (90 mg) were the only ones to show significant changes in the long-chain fatty acid profile (AAIC Presentation 2018). The cognitive outcomes, based on ADAS-Cog11, were also influenced by ApoE4 genotype, but due to the small numbers, it is not clear if the differences are clinically meaningful. Since T3D-959 is primarily geared toward improving both peripheral and central metabolism, it is likely to be most effective in patients with cerebral hypometabolism. Since ApoE is a lipid carrier and influences lipid levels, a lipid metabolism modulating therapy, like T3D-959, may be particularly beneficial in ApoE4 carriers, but more studies are needed.

Aging and related health concerns: T3D-959 may favorably modulate the peripheral metabolic profile. It shows anti-diabetic activity in preclinical models.

Types of evidence:

- 1 clinical trial
- Several laboratory studies

Diabetes: POTENTIAL BENEFIT

Before it was acquired by T3D Therapeutics, the dual PPAR δ /PPAR γ T3D-959 agonist was being developed for Type 2 diabetes by Dara Therapeutics under the name DB959. In the preclinical diabetes models, the db/db mouse, the Zucker Diabetic Fatty rat, and the Zucker Fatty fa/fa rat, DB959 (10 mg/kg/day) improved insulin sensitivity and reduced plasma glucose by 48 to 63%. Fat-fed DIO mice treated with DB959 gained a similar level of weight relative to vehicle-treated mice (7% vs 5%), which was lower than those treated with the thiazolidinedione, rosiglitazone (11%). In the hApo-A1 mouse model of hypercholesteremia, treatment with DB959 led to a 38% reduction in plasma triglycerides and 53% increase in HDL-c. Similar effects were seen in fat-fed hamsters. DB959 dose dependently increased fatty acid β -oxidation in skeletal muscle cells, and increased cholesterol transport in macrophages.

In the exploratory Phase 1/2 study in AD patients ([NCT02560753](#)), peripheral metabolic parameters were assessed ([AAIC Presentation 2018](#)). Based on a plasma metabolomics study, there was a shift in lipid metabolism consistent with increased beta oxidation of fatty acid. This included an increase in fatty acid-derived acylcarnitine species. There were also decreases in certain ceramide species which are implicated in metabolic disease, at doses of 30 and 90 mg. The branch-chained amino acids, leucine, isoleucine, and valine, as well as some of their major metabolites, which are implicated in insulin resistance, were decreased at the 90 mg dose.

These studies suggest that T3D-959 has anti-diabetic properties, and may regulate metabolic homeostasis in the periphery as well as the CNS. T3D-959 may also be investigated for non-alcoholic fatty liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH) (T3D Therapeutics [website](#)).

ZLY06: The dual PPAR δ /PPAR γ partial agonist ZLY06 (20 mg/kg oral) was found to improve glycemic control in the high-fat diet/streptozotocin and ob/ob rodent models of diabetes without causing weight gain [12]. It also improved the blood lipid profile in ob/ob mice by reducing triglycerides, total cholesterol, and LDL-c. In the methionine choline-deficient (MCD)-diet induced NASH model in db/db

male mice, ZLY06 (30 mg/kg) treatment during the induction period reduced liver enzymes ALT and AST, and reduced liver total cholesterol and triglyceride content to a greater degree than elafibranor (PPAR α/δ agonist) [13]. The attenuation of liver inflammation, oxidative stress, fibrosis, and NASH score was comparable to elafibranor. However, ZLY06 was found to induce hepatotoxicity in normal C57BL/6J mice via the upregulation of CD36 and inhibition of Akt signaling in the liver [14].

Safety: T3D-959 has been generally safe and well-tolerated in clinical trials, thus far. Possible side effects include muscle weakness and cramps, but were low frequency.

Types of evidence:

- 3 clinical trials
- Several laboratory studies

In a Phase 1 single ascending dose (SAD) (100-fold dose range) study in healthy volunteers (n=76), T3D-959 was well-tolerated at doses up to at least 200 mg. Similarly, in a Phase 1b multiple ascending dose (MAD) study in healthy volunteers (n=32), it was well-tolerated throughout the 40-fold dose range tested ([Press release](#), T3D Therapeutics [website](#)). Unlike thiazolidinediones, T3D-959 has not been associated with weight gain.

In an open-label Phase 2a trial ([NCT02560753](#)) in patients with mild to moderate AD, T3D-959 up to 90 mg for 14 days was generally safe and well-tolerated [7]. The drug showed dose-dependent exposure. Of the 4 out of 34 patients who experienced adverse events, only one was deemed to be treatment-related, which was muscular weakness. There were no abnormalities on clinical laboratory tests or vital signs in the four patients who participated in an 18-week extension study (15 mg QD).

T3D-959 was generally well-tolerated at doses of 15 mg, 30 mg, and 45 mg per day for 24 weeks in the Phase 2 PIONEER RCT in patients with mild to moderate AD ([NCT04251182](#)). Topline results indicate that the rate of adverse events was similar between those treated with T3D-959 and placebo (37.3% vs. 43.1%), with no treatment-related serious adverse events. There was one discontinuation due to drug-related mild peripheral edema. There were no particular adverse event classes more frequent with T3D-959 ([Press release](#)).

Drug interactions: Interactions for T3D-959 have not yet been established, but due to its PPAR γ agonist activity, some of the interactions may be similar as for thiazolidinediones. It may also have interactions with anti-diabetics.

Sources and dosing:

T3D-959 is not currently approved for use in humans outside of clinical trials. A safe and effective dose has not yet been established for any condition. It is being developed by [T3D Therapeutics](#) for Alzheimer's disease. Based on the results of its Phase 2 trial in patients with mild-to-moderate AD, T3D-959 will be tested at a dose of 30 mg/per day, orally, in a Phase 2/3 trial in this population.

Research underway:

According to [Clinicaltrial.gov](#), there is currently registered trial for T3D-959 that, to date, has not yet started recruiting.

T3D-959 will be tested in a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled trial in patients with mild to moderate AD (estimated n=376) ([NCT06964230](#)). It will be tested at a dose of 30 mg per day, orally for 78 weeks. The co-primary endpoints are the change from baseline to end of treatment in ADAS-Cog13 and ADCS-iADL. Secondary outcomes include change in the A β 42/40 ratio, change on the CDR-global, change on the CDR-sum of boxes, and change on the Alzheimer's Disease Rating Scale (iADRS). The trial has an expected start date in 2026, and an expected completion date in 2031.

Search terms:

Pubmed, Google: T3D-959

- Alzheimer's disease, diabetes, clinical trials, safety

Websites visited for T3D-959:

- [Clinicaltrials.gov](#)
- [PubChem](#)
- [Cafepharm](#)

References:

1. Tong M, Deochand C, Didsbury J *et al.* (2016) T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. *J Alzheimers Dis* **51**, 123-138 <https://pubmed.ncbi.nlm.nih.gov/26836193>
2. Govindarajulu M, Pinky PD, Bloemer J *et al.* (2018) Signaling Mechanisms of Selective PPAR γ Modulators in Alzheimer's Disease. *PPAR Research* **2018**, 2010675 <https://doi.org/10.1155/2018/2010675>.
3. Heneka MT, Fink A, Doblhammer G (2015) Effect of pioglitazone medication on the incidence of dementia. *Annals of Neurology* **78**, 284-294 <https://onlinelibrary.wiley.com/doi/abs/10.1002/ana.24439>.
4. Chou P-S, Ho B-L, Yang Y-H (2017) Effects of pioglitazone on the incidence of dementia in patients with diabetes. *Journal of Diabetes and its Complications* **31**, 1053-1057 <https://www.sciencedirect.com/science/article/pii/S1056872716306754>.
5. d'Angelo M, Castelli V, Catanesi M *et al.* (2019) PPAR γ and Cognitive Performance. *Int J Mol Sci* **20**, 5068 <https://pubmed.ncbi.nlm.nih.gov/31614739>
6. Aleshin S, Strokin M, Sergeeva M *et al.* (2013) Peroxisome proliferator-activated receptor (PPAR) β/δ , a possible nexus of PPAR α - and PPAR γ -dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses. *Neurochemistry International* **63**, 322-330 <https://www.sciencedirect.com/science/article/pii/S0197018613001836>.
7. Chamberlain S, Gabriel H, Strittmatter W *et al.* (2020) An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer's Disease. *J Alzheimers Dis* **73**, 1085-1103 <https://pubmed.ncbi.nlm.nih.gov/31884472>
8. Stanek J, Swearingen B, Strittmatter W *et al.* (2024) Phase 2 PIONEER Trial of Oral T3D-959 for the Treatment of Patients Diagnosed with Mild-to-Moderate Alzheimer's Disease: New Results in a Modified Intent-to-Treat Population. *Alzheimer's & Dementia* **20** <https://pmc.ncbi.nlm.nih.gov/articles/PMC11713541/>.
9. Tong M, Dominguez C, Didsbury J *et al.* (2016) Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies. *J Alzheimers Dis Parkinsonism* **6**, 238 <https://pubmed.ncbi.nlm.nih.gov/27525190>
10. de la Monte SM, Tong M, Schiano I *et al.* (2017) Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer's Disease. *Journal of Alzheimer's Disease* **55**, 849-864 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575806/>.
11. Steinke I, Govindarajulu M, Pinky PD *et al.* (2023) Selective PPAR-Delta/PPAR-Gamma Activation Improves Cognition in a Model of Alzheimer's Disease. *Cells* **12** <https://pmc.ncbi.nlm.nih.gov/articles/PMC10136457/>.
12. Li Z, Ren Q, Zhou Z *et al.* (2021) Discovery of the first-in-class dual PPAR δ/γ partial agonist for the treatment of metabolic syndrome. *European Journal of Medicinal Chemistry* **225**, 113807 <https://www.sciencedirect.com/science/article/pii/S0223523421006565>.
13. Zhou Z, Deng L, Hu L *et al.* (2020) Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis. *European Journal of Pharmacology* **882**, 173300 <https://www.sciencedirect.com/science/article/pii/S0014299920303927>.

14. Cai X, Zhang Q, Wang J *et al.* (2024) Novel Dual PPAR δ/γ Partial Agonist Induces Hepatic Lipid Accumulation through Direct Binding and Inhibition of AKT1 Phosphorylation, Mediating CD36 Upregulation. *Chemical research in toxicology* **37**, 1574-1587 <https://pubmed.ncbi.nlm.nih.gov/39235066/>.

Disclaimer: Cognitive Vitality Reports® do not provide, and should not be used for, medical advice, diagnosis, or treatment. You should consult with your healthcare providers when making decisions regarding your health. Your use of these reports constitutes your agreement to the [Terms & Conditions](#).

If you have suggestions for drugs, drugs-in-development, supplements, nutraceuticals, or food/drink with neuroprotective properties that warrant in-depth reviews by ADDF's Aging and Alzheimer's Prevention Program, please contact INFO@alzdiscovery.org. To view our official ratings, visit [Cognitive Vitality's Rating page](#).